A recent meta-analysis showed that administration of ezetimibe, an NPC1L1 inhibitor, improves liver inflammatory activity but not steatosis in patients with NASH [46]. The gene discussed is NPC1L1; the disease is metabolic dysfunction-associated steatohepatitis.